- Home
- FMST vs EDSA Comparison
FMST vs EDSA Comparison
Compare FMST & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMST
- EDSA
- Stock Information
- Founded
- FMST 2005
- EDSA 2015
- Country
- FMST Canada
- EDSA Canada
- Employees
- FMST N/A
- EDSA N/A
- Industry
- FMST Other Metals and Minerals
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- FMST Basic Materials
- EDSA Health Care
- Exchange
- FMST Nasdaq
- EDSA Nasdaq
- Market Cap
- FMST 15.8M
- EDSA 6.1M
- IPO Year
- FMST N/A
- EDSA N/A
- Fundamental
- Price
- FMST $1.60
- EDSA $1.73
- Analyst Decision
- FMST
- EDSA Strong Buy
- Analyst Count
- FMST 0
- EDSA 1
- Target Price
- FMST N/A
- EDSA $21.00
- AVG Volume (30 Days)
- FMST 34.3K
- EDSA 30.8K
- Earning Date
- FMST 01-01-0001
- EDSA 02-07-2025
- Dividend Yield
- FMST N/A
- EDSA N/A
- EPS Growth
- FMST N/A
- EDSA N/A
- EPS
- FMST N/A
- EDSA N/A
- Revenue
- FMST N/A
- EDSA N/A
- Revenue This Year
- FMST N/A
- EDSA N/A
- Revenue Next Year
- FMST N/A
- EDSA N/A
- P/E Ratio
- FMST N/A
- EDSA N/A
- Revenue Growth
- FMST N/A
- EDSA N/A
- 52 Week Low
- FMST $1.32
- EDSA $1.55
- 52 Week High
- FMST $3.50
- EDSA $5.99
- Technical
- Relative Strength Index (RSI)
- FMST 46.69
- EDSA 31.51
- Support Level
- FMST $1.43
- EDSA $1.73
- Resistance Level
- FMST $1.77
- EDSA $1.99
- Average True Range (ATR)
- FMST 0.20
- EDSA 0.19
- MACD
- FMST 0.05
- EDSA 0.02
- Stochastic Oscillator
- FMST 61.76
- EDSA 18.00
About FMST Foremost Lithium Resource & Technology Ltd. Common stock
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with significant historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.